Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Corboz (Bridgewater, United States of America), S. Gagnon (Sherbrooke, Canada), C. Brodeur (Sherbrooke, Canada), C. Laurent (Sherbrooke, Canada), A. Plaunt (Bridgewater, United States of America), V. Malinin (Bridgewater, United States of America), H. Gauani (Bridgewater, United States of America), D. Chun (Bridgewater, United States of America), Z. Li (Bridgewater, United States of America), D. Cipolla (Bridgewater, United States of America), W. Perkins (Bridgewater, United States of America), R. Chapman (Bridgewater, United States of America). Comparison of Treprostinil Palmitil Inhalation Suspension (TPIS) or Oral Sildenafil (Sild) in a Sugen/Hypoxia Rat Model of PAH.. 1481

Member's Comments

No comment yet.

Related content which might interest you: Safety, Tolerability (S&T) and Pharmacokinetics (PK) of Single and Repeat Inhaled Doses of Phosphoinositide-3-Kinase Delta Inhibitor (PI3Kd) GSK2269557, Delivered via the ELLIPTATM Device to Healthy Subjects in a Phase I Trial, Including Charcoal Block. Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017 Single dose pharmacokinetics of C16TR for Inhalation (INS1009) vs treprostinil inhalation solution Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Late Breaking Abstract - Lung deposition of two different ICS/LABA combinations with Dry Powder Inhaler (DPI) in asthmatic patients using Functional Respiratory Imaging (FRI). Source: International Congress 2019 – Imaging for prognostication and disease characterisation: 2019 update Year: 2019 (Oral) enoximone in asthma Source: ERJ Open Res, 6 (4) 00319-2020; 10.1183/23120541.00319-2020 Year: 2020 Pharmacokinetic (PK) interaction of ketoconazole (KC), clarithromycin (CM) and midazolam (MZ) with riociguat Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Exploring Efficacy and Safety of Oral Pirfenidone for Progressive, non-IPF Lung Fibrosis (RELIEF-Study) Source: International Congress 2017 – New ideas for the management of chronic lung diseases Year: 2017 Effects of Long Term Exogenous Apelin Application in Experimental Pulmonary Hypertension Model Created with Monocrotaline Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Effect of moderate hepatic impairment (MHI) on umeclidinium (UMEC) and vilanterol (VI) pharmacokinetics (PK) Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Effects of Inhaled Long Acting Muscarinic Antagonist (LAMA) on Lung Functions in Adult Stable Bronchiectasis Source: International Congress 2018 – COPD management Year: 2018 Effect of severe renal impairment (SRI) on umeclidinium (UMEC) and vilanterol (VI) pharmacokinetics (PK) Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 Cost Effectiveness Comparison of a Dry Powder Inhaler to a Metered Dose Inhaler plus Valved Holding Chamber based on a Functional Respiratory Imaging (FRI) Model Source: Virtual Congress 2021 – Difficult decisions on expected outcomes: availability of hospital resources and improvement of treatment adherence Year: 2021 The novel elastase inhibitor BAY 85-8501: Bioavailability and Food effect study to evaluate pharmacokinetics of tablet formulations Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Modelling Rhinovirus-16 (RV16) Infection using Human Precision Cut Lung Slices (PCLS) Source: Virtual Congress 2021 – Management of chronic cough and obstructive diseases Year: 2021 Safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single (SD) and repeat (RD) inhaled doses of a novel phosphoinositide 3-kinase δ inhibitor (PI3Kδ), GSK2269557, administered to healthy smokers Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014 Combining Inhalation by A Breath Actuated Nebuliser (BAN) With Exhalation Through An Oscillating Positive Expiratory Pressure Device (OPEP) Offers The Potential For Optimal Combined Therapy Source: International Congress 2019 – Treatments, adherence and psychosocial aspects of cystic fibrosis Year: 2019 Pharmacokinetic (PK) analysis of fluticasone furoate (FF), umeclidinium (UMEC) and vilanterol (VI) following triple therapy in healthy subjects Source: International Congress 2014 – Asthma and COPD management Year: 2014 Pharmacokinetics (PK) and safety of budesonide plus formoterol (BF) (160/4.5mcg) Spiromax® and BF (200/6mcg) Turbuhaler® following two inhalations (+/– charcoal [char] block) in healthy volunteers (HV) Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013 Pharmacokinetics (PK) and safety of budesonide plus formoterol (BF) (320/9mcg) Spiromax® and BF (400/12mcg) Turbuhaler® following two inhalations (+/– charcoal [char] block) in healthy volunteers (HV) Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD Year: 2013 Tiotropium respimat: Comparison of bronchodilator efficacy of 5 and 2.5 µg doses Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Understanding of Pharmacokinetics and Exposure Drives use of Nintedanib as a Positive Control Reference Item in a Rat Model of Bleomycin-Induced Fibrosis Source: International Congress 2019 – New mechanistic insights into pulmonary fibrosis Year: 2019